Karsten Witt
President chez KW Biotech Consulting LLC
Profil
Karsten Witt currently works at KW Biotech Consulting LLC, as President from 2013.
Dr. Witt also formerly worked at Topotarget A, as Director in 2011, OSI Pharmaceuticals, Inc., as Senior Vice President-Pharmaceutical Operations, Array BioPharma, Inc., as Vice President-Clinical Sciences from 2011 to 2013, and Black Diamond Therapeutics, Inc., as Chief Medical Officer & VP-Clinical Development from 2021 to 2022.
Dr. Witt received his doctorate degree in 1985 from the University of Copenhagen.
Postes actifs de Karsten Witt
Sociétés | Poste | Début |
---|---|---|
KW Biotech Consulting LLC | President | 01/02/2013 |
Anciens postes connus de Karsten Witt
Sociétés | Poste | Fin |
---|---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08/09/2020 |
ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01/01/2013 |
OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
TOPOTARGET A/S | Director/Board Member | - |
Formation de Karsten Witt
University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Topotarget A/S
Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
KW Biotech Consulting LLC |